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Polymyositis, invasion of non-necrotic muscle fibres, and
the art of repetition
Gerald J D Hengstman, Baziel G M van Engelen
The presence of cellular inflammatory infiltrates with invasion of non-necrotic muscle fibres has
become a prerequisite for the diagnosis of polymyositis, but a structured literature search shows that
the research evidence is insufficiently strong for this histological feature to be used as a diagnostic
criterion
A dispute has erupted over the diagnostic criteria for
polymyositis, a disorder characterised by progressive
muscle weakness and the presence of inflammatory
infiltrates in skeletal muscle tissue that could leave
many myositis patients diagnostically adrift and
excluded from receiving potentially effective treat-
ment. It might also lead to the results of clinical studies
performed by one specialist not being accepted by
another because of disagreement over the diagnostic
criteria used. The dispute focuses on the histopatho-
logical characteristics of polymyositis and whether
the presence of inflammatory infiltrates invading
non-necrotic muscle fibres is a prerequisite for the
diagnosis.
To examine the validity of this presumed histological
characteristic of polymyositis, we traced the original
source of this statement by performing a structured
literature search. We subsequently studied the original
source in the light of present day knowledge onmyositis.
The dispute
The idiopathic inflammatory myopathies are a group
of heterogeneous disorders characterised by acquired
progressive muscle weakness and inflammatory infil-
trates in skeletal muscle tissue. The three main
disorders in this group are dermatomyositis, polymy-
ositis, and inclusion body myositis. These diseases
differ strongly from each other, both clinically and
pathophysiologically. Dermatomyositis seems to be a
humorally mediated angiopathy resulting in myositis
and a typical dermatitis.1 Polymyositis is traditionally
seen as an inflammatory myopathy mediated by
cytotoxic T cells, which can occur in the context of
another inflammatory connective tissue disease such
as systemic sclerosis.1 Inclusion body myositis, which is
seen mainly in elderly people and is clinically
characterised by slowly progressive asymmetric muscle
weakness, is thought to be a degenerative myopathy
with secondary inflammation.2 3
Diagnosing dermatomyositis, polymyositis, or
inclusion body myositis depends on a combination of
clinical characteristics, results of laboratory investiga-
tions (including levels of muscle associated enzymes,
serology, electromyography, and muscle biopsy), and
responses to treatment. Only rarely are all typical
features of a disease present simultaneously, and the
correct diagnosis may only become apparent over
time. Dermatomyositis and polymyositis are, unlike
inclusion body myositis, multi-specialty disorders, and
patients with these diseases are treated by rheumatolo-
gists, neurologists, dermatologists, and specialists in
internal medicine.
The diagnoses of dermatomyositis and inclusion
body myositis are straightforward, but diagnosing
polymyositis is controversial. Over the past year, a
dispute, primarily between rheumatologists and
neurologists, has erupted over the diagnostic criteria for
polymyositis. Rheumatologists tend to rely on clinical
signs, symptoms, and serology, whereas neurologists
rely more on histopathology in order to exclude other
myopathies. This dispute was recently aired in the
Lancet by a group of rheumatologists commenting on a
review article on polymyositis and dermatomyositis.1 4
Another example is an article accompanied by an
editorial, and the correspondence these elicited,
published in Neurology in which the authors stated that
polymyositis hardly exists.5–9
While rheumatologists usually use the Bohan and
Peter criteria for polymyositis,10 neurologists feel a
need to confirm the diagnosis, and to exclude other
myopathies, by muscle biopsy. In their view, polymyosi-
tis is histologically characterised by the presence of
endomysial inflammatory infiltrates consisting of CD8
T cells invading non-necrotic muscle fibres that
express major histocompatibility complex class I
molecules on the sarcolemma, as shown by the criteria
proposed in the recent Lancet review.1
The history examined
To solve this dispute, we not only need rheumatologists
and neurologists to understand each other’s viewpoint,
but we also need to identify the source of the dispute,
preferably from a historical perspective. We therefore
Polymyositis is histopathologically characterised by cellular
inflammatory infiltrates with invasion of non-necrotic muscle fibres
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examined the historical background and validity of the
histopathological definition of polymyositis by study-
ing the medical literature in a structured manner.
We started with the recent Lancet article on
dermatomyositis and polymyositis.1 The authors write
“in polymyositis, multifocal lymphocytic infiltrates
surround and invade healthy muscle fibres” and
provide six references to support this statement: four
review articles and two book chapters (see figure).w1-w6
We then studied the four reviews (the book chapters did
not contain primary records or original data). All these
reviews mention the presumed histological feature of
polymyositis, and three of them provide references for
this statement. In total 20 references are provided,
including three of the initial six references.11–14 w1 w3 w5 w7-w17
Examination of all journal articles resulted in our
being referred to several other articles and book chap-
ters. In total, we were referred to 205 references in
order to find the original source of the statement that
polymyositis is characterised by invasion of non-
necrotic muscle fibres. Several of the references refer to
each other, resulting in 28 original references.11–14 w1-w24
Only four of these references provide original data.11–14
The other 24 references are review articles (14), books
(8), abstracts (1), or non-existent (1). It was remarkable
that 19 of the 28 identified references were from just
two research groups.12 14 w1 w3 w5-w8 w10 w12-w15 w17-w19 w22-w24
The original sources
In the most recent of the four articles containing
original data, Emslie-Smith et al studied the expression
of major histocompatibility complex class I antigens, the
immunolocalisation of interferon subtypes, and T cell
mediated cytotoxicity in patients with dermatomyositis,
polymyositis, inclusion body myositis, or Duchenne’s
muscular dystrophy, and normal controls.14 The authors
found invasion of non-necrotic muscle fibres by inflam-
matory infiltrates in all the diseases studied except
dermatomyositis. They did not quantify their findings.
In the second article Ringel et al quantitatively
assessed the histopathology of 57 patients with myosi-
tis.13 They included patients with dermatomyositis and
polymyositis diagnosed according to the Bohan and
Peter criteria and excluded all patients with inclusion
body myositis without specifying how these patients
had been identified.10 With the exception of perifas-
cicular atrophy, no histological feature could invariably
distinguish the different disorders. Invasion of non-
necrotic muscle fibres was not mentioned.
The earliest article is a review article on the pathol-
ogy of inflammatory muscle disorders and includes
some observations made by the authors.11 The authors
state that they observed “mononuclear cells (indenting)
the cytoplasm of non-necrotic muscle cells” in eight
out of 16 polymyositis patients. They did not provide
clinical data or specify the diagnostic criteria used.
In the fourth article, published in 1984, Arahata
and Engel studied the histopathological features of
patients with dermatomyositis, polymyositis, inclusion
body myositis, scleroderma, or Duchenne’s muscular
dystrophy, and normal controls.12 They found invasion
of non-necrotic muscle fibres in patients with
Duchenne’s muscular dystrophy, dermatomyositis,
polymyositis, and inclusion body myositis. The invasion
was clearly more extensive in polymyositis and
inclusion body myositis than in the other diseases, and
the authors concluded that polymyositis (and inclusion
body myositis) was characterised by invasion of
non-necrotic muscle fibres by endomysial located
inflammatory infiltrates. Crucial for the validity of this
conclusion is how these patients were diagnosed, and
especially how inclusion body myositis was differenti-
ated from polymyositis.
Arahata and Engel’s patients
Although it had been described earlier, inclusion body
myositis was not recognised as a distinct disease entity
until the early 1980s. Until then, patients usually had
been diagnosed with “treatment resistant” polymyositis.
The “treatment resistance” reflects the most important
clinical difference between inclusion body myositis
and polymyositis: polymyositis responds to immuno-
suppressive and immunomodulatory treatment,
whereas inclusion body myositis does not.
Histopathologically, inclusion body myositis can
easily be mistaken for polymyositis because both
disorders are characterised by endomysial inflammatory
infiltrates with invasion of non-necrotic muscle fibres.3
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The histological difference between inclusion body
myositis and polymyositis consists of the presence of
basophilic rimmed vacuoles, amyloid depositions, and
accumulation of cytoplasmic and intranuclear tubulo-
filamentous inclusions under electron microscopy in
inclusion body myositis.3 However, these typical
features can be absent in the initial muscle biopsies
from patients with inclusion body myositis,3 15 and the
diagnosis of inclusion body myositis (as opposed to
polymyositis) in those cases relies almost entirely on
the typical clinical phenotype.3
Arahata and Engel’s diagnosis of myositis was
“based on conventional criteria,” for which the reader is
referred to the Bohan and Peter criteria and a review
article by Whitaker.10 16 Whitaker describes dermato-
myositis and polymyositis, and only mentions inclusion
body myositis in a classification table. Arahata and
Engel state that all their patients with a diagnosis of
inclusion body myositis had the typical histological
findings, including vacuoles and filamentous inclusions
shown by electron microscopy. All other cases, includ-
ing those we would now identify as inclusion body
myositis on the basis of the typical clinical phenotype
(which was not fully recognised at the time the article
was published) but without the vacuoles and filamen-
tous inclusions, were diagnosed as polymyositis.3 It is
thus conceivable that some of Arahata and Engel’s
polymyositis patients actually had early inclusion body
myositis.
This is in accordance with the results of a recent
study by Van der Meulen et al, which found that myosi-
tis patients who met the histological criterion of
invasion of non-necrotic muscle fibres by endomysial
inflammatory infiltrates all had atypical polymyositis
with several clinical characteristics of inclusion body
myositis.5
Conclusions
Several conclusions can be drawn from our review of
the medical literature: some are applicable to medicine
in general and some to medical literature, and some
are important for doctors interested in myositis.
Firstly, an observation made in the past sometimes
escapes reassessment of its validity even if recent advances
in medical knowledge warrant such a reassessment. This
especially seems to be the case if conclusions are cited in
review articles and subsequent review articles cite only the
first review article instead of the original publication.
Through repetition, conclusions—even though they have
become invalid over time—become embedded in the
medical literature, the pathophysiological concepts of dis-
ease, and the minds of clinicians and researchers. Using
review articles as references can lead to authors not famil-
iarising themselves with the original publications. The use
of review articles as references is strongly encouraged by
the editorial limitations placed on the number of
references that authors can provide for a manuscript. By
lifting the restriction on the number of references, medi-
cal journals will probably become slightly thicker, but
their quality might increase significantly.
Secondly, some authors have a strong tendency to
refer to themselves.Of the 28 references we found in our
literature search, 68% were from only two research
groups, one of them not providing any original data.
This latter group referred to their own work 29 times, all
being review articles and book chapters.w1 w5-w8 w13-w20 w22 w23
Such repetition affects the opinion not only of readers
but also of the authors. By repeating oneself, one can
become convinced of the validity of one’s own
statement. Furthermore, admitting that one’s conclu-
sions are incorrect becomes practically impossible
because credibility and ego are at stake. Editorial
boards of medical journals should be more critical with
regard to the use of references, especially because they
have limited their number. References should be
checked for their validity, and articles (especially review
articles) should not unnecessarily refer to other review
articles and book chapters but mainly to the original
publications. We require detailed descriptions of the
methods used for laboratory experiments, but appar-
ently we feel no need for a detailed description of the
sources of statements on pathophysiology and
concepts of disease.
As for the field of myositis, invasion of non-necrotic
muscle fibres by endomysial inflammatory infiltrates is
a feature of inclusion body myositis and possibly of
polymyositis, but in the latter disease this still needs to
be confirmed. Diagnostic criteria in which the presence
of this histopathological feature is a prerequisite for a
diagnosis of polymyositis are erroneous and are not
based on solid original data.
Myositis is a true multi-specialty disorder, and it
must be recognised as such by all who deal with myosi-
tis patients. The current dispute can be turned into a
positive development if we recognise that we now need
to bridge the gap between dermatologists, internists,
rheumatologists, and neurologists. Internationally
agreed criteria, acceptable to all, need to be developed.
The recent ENMC (European Neuro Muscular Centre)
workshop on idiopathic inflammatory myopathies is a
first step in that direction.17 Hopefully, this initiative will
be followed so that we finally can agree on diagnostic
criteria for these enigmatic diseases.
Summary points
The recent dispute over the diagnostic criteria for
polymyositis, which is potentially harmful for
patients, focuses on whether polymyositis is
histologically characterised by inflammatory
infiltrates invading non-necrotic muscle fibres
From a historical perspective, this statement may
not be valid because the polymyositis patients in
the original source of this statement may actually
have had inclusion body myositis and not
polymyositis
Diagnostic criteria in which the presence of this
histopathological feature is a prerequisite for the
diagnosis polymyositis are erroneous and are not
based on solid original data
This invalid feature seems to have become
embedded in the medical literature through a
combination of authors’ tendency to use review
articles as references, authors not familiarising
themselves with original publications, and authors
who have a strong tendency to refer to themselves
Experts’ eye view
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Meeting mania 2004
David S Goldbloom
The rise in the number of meetings occurring every day in healthcare institutions shows no sign of
abating. What are the factors contributing to this “meeting mania,” and is there anything that can be
done to counter it?
Ten years ago Abraham Bergman described the
epidemic phenomenon in healthcare institutions of
“meeting mania.”1 He lamented the exponential
increase in the frequency of meetings and ascribed it to
the proliferation of administrators and managers. He
observed that meetings served several illusory pur-
poses: communication, decision making, and responsi-
bility. He bravely called for a moratorium on meetings
for 30 days and then a gradual and filtered reintroduc-
tion with better clarity of purpose, time limits, and for-
mat. He advocated email as a useful alternative to
meetings, or voicemail for communication purposes.
What has the past decade wrought? From the per-
spective of a former physician-in-chief of an academic
health sciences centre, meeting mania has become
pandemic, rivaling the 1918 influenza outbreak. Meet-
ings, task forces, and retreats (they are never advances)
pervade our agendas more than ever before. In the
past 10 years several phenomena have contributed to
the worsening of this problem.
Electronic wizardry
Most of us have at least the skeleton of our daily sched-
ules captured on software that is typically uniform
throughout a hospital. In order to schedule meetings,
this software has the capacity to search the schedules of
all potential attendees to find common times when
they are free; an email follows asking you to attend,
smugly knowing that you have no conflicting commit-
ments. Orwellian concerns that your schedule of daily
activities is freely available to others notwithstanding,
there is a fundamental assumption in this software that
exacerbates meeting mania: if you are not “busy” as
reflected by a scheduled event in your electronic calen-
dar (typically a meeting), ergo you are not working. In
fact, the opposite is probably true—the only time you
may be doing productive work is when you are not in a
meeting. Some colleagues have taken to blocking off
time in their electronic schedules simply to render
themselves impervious to the feeding frenzy of
meeting schedulers.
Perhaps naively, Bergman hoped that email would
serve as a better communication vehicle than face to
face contact. At our hospital, it is not uncommon for
senior managers to receive between 60 and 100 emails
in a day. Answering email now counts as work. In the
absence of a defined etiquette of electronic communi-
cation, the tyranny of distribution lists creates a
barrage, at no extra cost to the sender, of information
that may be only peripherally relevant to any
individual recipient. Furthermore, the tragic alignment
of the “reply to all” button adjacent to the “reply” but-
ton on the toolbar is a fundamental error of human
engineering. It means that all too often one learns that
a colleague is unable to attend a meeting to which 30
people have been invited or is simply saying, “Thanks.”
Who cares? Many of us succumb to the Sisyphean
temptation of answering email as soon as it comes in,
in the vain hope that the inbox will remain empty. It
never does. More moderate souls reserve a time at the
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